Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial

Published:2020-10 Issue:10 Volume:26 Page:1564-1568
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Algazi Alain P.^ORCID,Othus Megan^ORCID,Daud Adil I.^ORCID,Lo Roger S.,Mehnert Janice M.,Truong Thach-Giao,Conry Robert,Kendra Kari,Doolittle Gary C.,Clark Joseph I.,Messino Michael J.,Moore Dennis F.,Lao Christopher,Faller Bryan A.,Govindarajan Rangaswamy,Harker-Murray Amy,Dreisbach Luke,Moon James,Grossmann Kenneth F.,Ribas Antoni^ORCID

Funder

NIH/NCI grants to SWOG supporting the research presented here are listed and apply to all co-authors.

U.S. Department of Health & Human Services | NIH | National Cancer Institute

In addition to SWOG grants listed above.

In addition to SWOG grants listed under the corresponding author that apply to all coauthors.

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-020-1060-8.pdf

Reference20 articles.

1. Das Thakur, M. et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251–255 (2013).

2. Moriceau, G. et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 27, 240–256 (2015).

3. Ascierto, P. A. et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 17, 1248–1260 (2016).

4. Long, G. V. et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386, 444–451 (2015).

5. Dummer, R. et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 19, 1315–1327 (2018).

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs;eLife;2024-09-10

2. Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs;eLife;2024-09-10

3. Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting;Melanoma Research;2024-08-30

4. Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs;2024-07-31

5. Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer;JAMA Oncology;2024-07-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3